ClinicalTrials.gg
RecruitingNCT06348576Updated May 21, 2024

Phase III Study to Evaluate the Efficacy and Safety of AD-209

A Phase 3 interventional study of AD-209 and AD-2091 in Hypertension,Essential, sponsored by Addpharma Inc.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.

Started
2024
with 3 others
Phase 3
5 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is one of 4 that started in 2024, is one of 5 in phase 3, and was the 7th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Essential Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

Read the detailed description

Condition or disease : hypertension

03

Conditions studied

  • Hypertension,Essential
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Other inclusions applied

Exclusion criteria

Exclusion Criteria:

  • Orthostatic hypotension with symptom
  • Other exclusions applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Test group

    AD-209+AD-2091 Placebo

    Drug: AD-209 · Drug: AD-2091 Placebo

  • Active comparator
    Control group

    AD-2091+AD-209 Placebo

    Drug: AD-2091 · Drug: AD-209 Placebo

Interventions

  • DrugAD-209

    PO, Once daily(QD), 8weeks

  • DrugAD-2091

    PO, Once daily(QD), 8weeks

  • DrugAD-209 Placebo

    PO, Once daily(QD), 8weeks

  • DrugAD-2091 Placebo

    PO, Once daily(QD), 8weeks

06

What researchers measure

Primary outcomes

  1. Change rate of MSSBP

    Change from baseline in mean sitting systolic blood pressure

    Time frame: Baseline, Week 8

07

Study locations

1 of 1 sites recruiting
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Chang Gyu Park, M.D., Ph.D · Contact
    • Chang Gyu Park, M.D., Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Feb 2025, 9 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's planned 9 months is below that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 4, 2024
StartActual
May 20, 2024
Primary completionEst.
Feb 2025
CompletionEst.
Feb 2025
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348576
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
May 20, 2024
Primary completion
Feb 2025 (estimated)
Completion
Feb 2025 (estimated)
Last update
May 21, 2024

Study contacts

Kyung Tae Kim, D.V.M
Contact
ktkim@addpharma.co.kr
82-031-891-5661
Chang Gyu Park, M.D., Ph.D
Contact
Chang Gyu Park, M.D., Ph.D
principal investigator · Korea University Guro Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AD-209

Start the discussion